Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | LMNA | P02545 | 7/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.78 |
| ▸ | HTR2A | P28223 | 5/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.78 |
| ▸ | HRH1 | P35367 | 5/20 | 0.78 |
| ▸ | DRD3 | P35462 | 5/20 | 0.78 |
| ▸ | HTR2B | P41595 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.78 |
| ▸ | HTR2C | P28335 | 4/20 | 0.78 |
| ▸ | HTR1A | P08908 | 4/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL1069857 | 0.99 | MAPT (0.76) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL1037541 | 0.99 | MAPT (0.76) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL1069999 | 0.91 | LMNA (0.78) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| SCHEMBL21525461 | 0.90 | MAPT (0.76) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL1069230 | 0.90 | MAPT (0.76) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL1069229 | 0.90 | LMNA (0.79) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL3194369 | 0.89 | LMNA (0.75) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL144029 | 0.89 | LMNA (0.75) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL1071642 | 0.89 | LMNA (0.84) | MAPTLMNAMAPK1ADRA2ADRD2 | |
| Perphenazine SCHEMBL28456705 | 0.88 | MAPT (0.88) | MAPTLMNAMAPK1ADRA2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975251-B2 | Methods of improving cognitive functions | BAR-ILAN UNIVERSITY (IL) | 2015-03-10 | — | — | US | claimed |
| US-20130150352-A1 | CRYSTALLINE FORMS OF THE TRI-MESYLATE SALT OF PERPHENAZINE-GABA AND PROCESS OF PRODUCING THE SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-06-13 | — | — | US | claimed |
| US-8377929-B2 | Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-02-19 | — | — | US | claimed |
| EP-2539857-A2 | CRYSTALLINE FORMS OF THE TRI-MESYLATE SALT OF PERPHENAZINE-GABA AND PROCESS OF PRODUCING THE SAME | Ramot at Tel Aviv University, Ltd. (IL) | 2013-01-02 | — | — | EP | claimed |
| CN-102762211-A | Methods of improving cognitive function | BIOLINERX LTD | 2012-10-31 | — | — | CN | claimed |
| EP-2509603-A1 | METHODS OF IMPROVING COGNITIVE FUNCTIONS | BIOLINERX LTD. (IL) | 2012-10-17 | — | — | EP | claimed |
| WO-2011104637-A9 | CRYSTALLINE FORMS OF THE TRI-MESYLATE SALT OF PERPHENAZINE-GABA AND PROCESS OF PRODUCING THE SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-01-05 | — | — | WO | claimed |
| WO-2011104637-A2 | CRYSTALLINE FORMS OF THE TRI-MESYLATE SALT OF PERPHENAZINE-GABA AND PROCESS OF PRODUCING THE SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-09-01 | — | — | WO | claimed |
| US-20110178073-A1 | METHODS OF IMPROVING COGNITIVE FUNCTIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-07-21 | — | — | US | claimed |
| WO-2011070579-A1 | METHODS OF IMPROVING COGNITIVE FUNCTIONS | BIOLINERX LTD. (IL) | 2011-06-16 | — | — | WO | claimed |
| US-20100063034-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2010-03-11 | — | — | US | claimed |
| US-7544681-B2 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-06-09 | — | — | US | claimed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-2525830-B1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2016-05-11 | — | — | EP | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178073-A1 | METHODS OF IMPROVING COGNITIVE FUNCTIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-07-21 | — | — | US | disclosed |
| WO-2011070579-A1 | METHODS OF IMPROVING COGNITIVE FUNCTIONS | BIOLINERX LTD. (IL) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | DRD2 292/4885MAPT 1232/4885LMNA 1767/4885 |
| US-20100063034-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | DRD2 32/4885MAPT 432/4885LMNA 4629/4885 |
| US-20110178073-A1 | METHODS OF IMPROVING COGNITIVE FUNCTIONS | CHAT, GABRE, BCHE | DRD2 722/4885MAPT 399/4885LMNA 3645/4885 |
| US-20130150352-A1 | CRYSTALLINE FORMS OF THE TRI-MESYLATE SALT OF PERPHENAZINE-GABA AND PROCESS OF PRODUCING THE SAME | DPP4, GABBR1, SLC6A1 | DRD2 247/4885MAPT 47/4885LMNA 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.